welcome to cyprotexcloe® screencloe® selectcloe® predict
home > investor relations

Highlights

Interim Results to 30 June 2009

  • Revenues up 9% to £2.45 million (H1 2008: £2.25 million)
  • Net profit up to £157,000 (H1 2008: profit £56,000)
  • Cash and cash equivalents at 30 June £1.72 million (H1 2008: £276,000)
  • Fully diluted EPS increased to 0.09p (H1 2008: 0.04p)

Commenting on the results, Steve Harris, Chairman of Cyprotex PLC, said:

"With the new management changes now in place, the Company has performed well in the first half of 2009, consolidating revenue the gains and profitability of 2008. In the face of a challenging market for the CRO industry, our investments in additional products and services are beginning to bear fruit with the generation of significant revenues and new customers and we will continue to drive this momentum forward into 2010."

Download Interim results to 30 June 2009

contact

Find out more about us.

Investor Relations
Anthony Baxter/Mark Warburton

Call on +44 1625 505100

contact
careerscontactlegalprivacy
This website was last updated
on 19th March 2010
This website is intended to assist investors, industry participants, customers and employees to understand Cyprotex’s global operations and ambitions.
Certain information and detail is disclosed in the interest of compliance of AIM Rule 26.